Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

Share Price Information for Craven House Capital (CRV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.15
Ask: 0.25
Change: 0.00 (0.00%)
Spread: 0.10 (66.667%)
Open: 0.20
High: 0.20
Low: 0.20
Prev. Close: 0.20
CRV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of 50.1% shareholding in Finishtec

2 Jan 2013 09:28

RNS Number : 6373U
Craven House Capital PLC
02 January 2013
 

2 January 2013

 

CRAVEN HOUSE CAPITAL PLC

("Craven House" or the "Company")

 

Acquisition of 50.1% shareholding in "Finishtec - Acabamentos Técnicos em Metais Ltda - ME"

 

The Company today announces that it has agreed to purchase 17,502 shares in Finishtec - Acabamentos Técnicos em Metais Ltda. - ME ("Finishtec") representing 50.1% of Finishtec's issued share capital. The shares are being purchased at a price of approximately $57 per share, amounting to a total consideration of $1,000,000, from the founding partners of Finishtec (the "Shareholders"). Simultaneously, the Shareholders have agreed to subscribe for 49,739,760 new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") for 1.25p per share, amounting to an aggregate subscription of £621,747 (approximately equivalent to $1,000,000).

 

Finishtec is a Brazilian manufacturing company, based in Curitiba, with net assets of over $1,000,000. Founded in 1998, Finishtec specialises in the manufacture of industrial electrical switching, distribution and insulating equipment for the domestic power sector in Brazil. It has a strong track record in the development of new technological practices, and has recently launched a new product line targeting the renewable energy sector. Finishtec benefits from an impressive list of blue-chip clients, which include ABB, Siemens, Alstom, Toshiba and Odebrecht. Its turnover has averaged circa $680,000 annually over the past three years, although this is expected to more than double with sales from the new renewable energy product line. 

 

Whilst Craven House will be the major shareholder, it will remain a passive investor with no involvement in the management of the operation. Craven House will assist Finishtec with the funding of additional inventory, enabling Finishtec to secure larger orders

 

Mark Pajak, Acting Chairman, commented, "Finishtec's prospects, in what is a booming sector within a rapidly growing economy, are very exciting, and we are extremely pleased that Craven House has been able to secure this position.

 

Finishtec has demonstrated an impressive ability to continually develop and adapt its product offering. The focus on business development has helped the company establish strong relationships with some of the largest industrial conglomerates in the world. We believe that Finishtec is poised to build substantial market share in the highly specialised renewable energy sector in the coming years.

 

Craven House intends to utilise its asset base and banking relationships to provide Finishtec with the support needed to enable it to build inventory and secure much larger orders than it has been able to in the past. The credit and capital markets in emerging economies such as Brazil tend not to serve small and mid sized manufacturers. This gap in the market creates an environment in which very well run small-to-medium sized enterprises, such as Finishtec, are unable to access the capital they need to expand. Craven House aims to provide this support on terms that will give Finishtec a competitive advantage, so enabling it to increase revenues and enhance profit margins.

 

Once again we have demonstrated our ability to secure an excellent asset while continuing to value Craven House shares at a premium to the market price - a clearly defined and central aspect of our investment strategy. This and all other recent transactions have valued the Company's shares at 1.25p per share.

 

We were able to achieve this because Craven House is recognised as a value added shareholder that not only supplies capital but also leverages its expertise and relationships in the markets within which it operates. "

 

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place on 8th January 2013. The shares will rank pari passu with the existing issued ordinary shares.

 

Following the issue of the new ordinary shares, the Company's total issued share capital will consist of 547,776,501ordinary shares with each share carrying the right to one vote. The Company has no ordinary shares held in treasury. The total of 547,776,501 ordinary shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

 For further information please contact:

 

Craven House Capital Plc:

www.cravenhousecapital.com

 

Alexandra Eavis

Non Executive Director & Company Secretary

 

Tel: 07590 831 323

Daniel Stewart & Company Plc:

(Nominated Adviser & Broker)

Antony Legge/James Thomas

Tel: 020 7776 6550

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQGCGDBIBGBGXD
Date   Source Headline
28th Feb 20247:00 amRNSInterim Results
4th Jan 20247:00 amRNSResult of Annual General Meeting
29th Nov 20232:48 pmRNSAnnual Results for year ended 31 May 2023
28th Nov 20234:08 pmRNSInvestee Companies' Update
16th Nov 20239:07 amRNSInvestee Companies’ Update: Garimon and Honeydog
23rd Oct 20237:00 amRNSInvestee company update: Bio Vitos
17th Oct 20237:46 amRNSInvestee Companies’ Update: Garimon and Honeydog
29th Aug 20231:34 pmRNSInvestee company update: Bio Vitos
3rd Jul 20231:32 pmRNSInvestee company update: Bio Vitos
3rd Mar 20236:15 pmRNSPortfolio Update
27th Feb 20233:30 pmRNSInterim Results
8th Feb 20237:00 amRNSInvestee company update: Bio Vitos
27th Jan 202311:33 amRNSResult of Annual General Meeting
29th Nov 20227:00 amRNSAnnual Results for Year Ended 31 May 2022
15th Nov 20222:42 pmRNSInvestee company update: Garimon Ltd
23rd Feb 20223:01 pmRNSInterim Results
21st Jan 202212:45 pmRNSResult of AGM
23rd Dec 20213:59 pmRNSNotice of AGM
29th Nov 20216:29 pmRNSAnnual Results for year ended 31 May 2021
24th Nov 20212:55 pmRNSInvestee company update: OneBas.Com Ltd.
26th Oct 20217:00 amRNSInvestee company update: YRRO Ltd
16th Mar 20211:06 pmRNSTR-1: Notification of major holdings
18th Feb 20213:07 pmRNSInterim Results
11th Feb 202111:21 amRNSTR-1: Notification of major holdings
5th Feb 202110:44 amRNSStatement Regarding Share Price Movement
18th Jan 20212:49 pmRNSResult of Annual General Meeting
21st Dec 20207:00 amRNSNotice of General Meeting
9th Dec 20207:00 amRNSInvestee Company Update: YRRO Ltd
3rd Dec 202012:43 pmRNSAnnual Results for year ended 31 May 2020
9th Nov 20209:45 amRNSChange of Auditor
9th Oct 20203:14 pmRNSTrading Update, Change of Auditor & 2020 Results
18th Sep 202010:57 amRNSInvestee company update: Magazinos.com
22nd Jun 20201:01 pmRNSTR-1: Notification of major holdings
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
3rd Jun 20201:27 pmRNSTR-1: Notification of major holdings
1st Jun 20202:05 pmRNSSecond Price Monitoring Extn
1st Jun 20202:00 pmRNSPrice Monitoring Extension
22nd May 20209:43 amRNSResult of General Meeting
5th May 202010:42 amRNSTR-1: Notification of major holdings
1st May 202010:58 amRNSPosting of Circular
1st Apr 20203:39 pmRNSCoronavirus and Business Update
23rd Mar 202012:19 pmRNSOn-line Platform Launched by Investee, Rosedog Ltd
20th Mar 20205:01 pmRNSNotification of major holdings
13th Mar 20207:00 amRNSSimultaneous exercise of five Option Agreements
27th Feb 202011:22 amRNSIssue of Equity and Directors' Dealing
27th Feb 20207:00 amRNSInterim Results
25th Feb 20209:16 amRNSNotification of major holdings
24th Feb 20207:00 amRNSCraven House signs 5 Non-binding Option Agreements
18th Feb 20202:54 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.